Nanocarriers Target the Eye for Better Ocular Drug Delivery
Ocular drug delivery faces major biological barriers. Nanocarriers could improve bioavailability, tissue targeting, controlled release, and treatment for difficult eye diseases.
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.